 ABINGDON, OXFORDSHIRE ACCESSWIRE May 18, 2020 Midatech Pharma PLC Midatech or the Company AIM:MTPH.L; NASDAQ:MTP, an RD; biotechnology company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce that it has entered into definitive binding agreements with institutional investors the Investors for the purchase in a registered direct offering the Offering of 1,818,182 of its American Depositary Shares ADSs each ADS representing five of the Companys ordinary shares the New Ordinary Shares at a purchase price of US1.65 per ADS equivalent to 0.27 per New Ordinary Share, for aggregate gross proceeds of US3.0 million 2.5 million. Additionally, in a concurrent private placement, the Company has agreed to issue to the Investors unregistered warrants to purchase up to an aggregate of 1,818,182 ADSs. 